Results

Total Results: 1,651 records

Showing results for "described".

281. Medication-Therapy-Management Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/medication-therapy-management_executive.pdf
     November 01, 2014 - represents a suite of health care services that have evolved out of the philosophy and processes described … In a few instances, described below, the evidence led us to conclude with a low strength of evidence … Most studies described intervention components in terms of “pharmaceutical care model” components or … This decision led us to include interventions described as “pharmaceutical care,” which were generally … These studies were often described as “clinical pharmacist interventions.”

282. Disposition of Comments for Evidence Report 221 Behavioral Programs for Diabetes Mellitus (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/diabetes-behavior-programs_disposition-comments.pdf
     September 28, 2015 - Peer Reviewer 3 Methods Methods for this report are very clear described and well justified. … When calculating contact hours, we assumed telephone calls (when described in number and serving as … TEP 1 Methods Appropriate methodology is used and described. Thank you for this comment. … We did allow for “equivalents” to blinding as described in the methods section (also see Supplementary … We agree and we have taken out this sentence since we described the concept better in another.

283. Disposition of Comments for CER 171 Noninvasive Testing for Coronary Artery Disease (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/coronary-artery-disease-testing_disposition-comments.pdf
     March 29, 2016 - relation to other tests such as downstream testing, cost-effectiveness, and availability are also described … The authors have candidly described the limitations of their review and analyses. Thank you. … Classification of patient pre-test risk was based on how it was described in the studies. … Information on the traditional test parameters of diagnostic accuracy are described in the background … Peer Reviewer 1 Clarity and Usability As described above, if the two additional questions (testing

284. Omega-3-Maternity Research-Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/omega-3-maternity_research-protocol.pdf
     May 18, 2015 - expand the scope of the review to include additional maternal and child outcomes, as noted above and described … graphically presents the key components of the study questions presented in section II and further described … fatty acids in maternal health Populations of interest, Exposure, Outcomes, and Effect modifiers are described … Data Abstraction and Data Management Data abstraction will follow the procedures described above. … Subgroup analyses will be explored within and across studies, based on the factors described in the

285. Disposition of Comments Report for Recurrent Nephrolithiasis in Adults (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/kidney-stone-prevention_disposition-comments.pdf
     July 26, 2012 - The studies are clearly described and the appendices provide additional detail. … Study characteristics are clearly described. Key messages are explicit. … The studies are clearly described and the appendices provide additional detail. … Finally, we agree with the reviewer that cost- effectiveness analyses as described are a http: … Limitations of individual studies are described adequately.

286. First- and Second-Generation Antipsychotics in Children and Young Adults: Systematic Review Update (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/antipsychotics-children-update-disposition-170621.pdf
     March 16, 2017 - The outcome measures and the scales used to obtain them are clearly described. … The other two arms should be described as cognitive therapy + risperidone (n=43) and cognitive therapy … The findings for these outcomes are described in the Detailed Analysis. … We only reported on data described by authors as major/serious AEs limiting treatment. … TEP 7 Discussion Discussions and conclusions are clear and adequately described.

287. First- and Second-Generation Antipsychotics in Children and Young Adults: Systematic Review Update (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/antipsychotics-children-update-disposition-170621.pdf
     March 16, 2017 - The outcome measures and the scales used to obtain them are clearly described. … The other two arms should be described as cognitive therapy + risperidone (n=43) and cognitive therapy … The findings for these outcomes are described in the Detailed Analysis. … We only reported on data described by authors as major/serious AEs limiting treatment. … TEP 7 Discussion Discussions and conclusions are clear and adequately described.

288. Disposition of Comments for CER 162 Diagnosis of Celiac Disease (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/celiac-disease_disposition-comments.pdf
     January 28, 2016 - Peer Reviewer 1 Methods The Methodology is sound and is described in appropriate detail. … Characteristics of studies are clearly described and the key messages provided are relevant quite clear … Peer Reviewer 2 Results Studies analyzed and outcomes were well described. … Discussion/Con clusion The implications are clearly stated, and limitations are also adequately described … Peer Reviewer 3 Discussion/Con clusion The sensitivity of the EMA test is described in the report

289. Abnormal-Uterine-Bleeding Research-Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/abnormal-uterine-bleeding_research-protocol.pdf
     November 21, 2011 - outcomes, timing, and setting (PICOTS) of interest for the proposed comparative effectiveness review are described … Methods The methodological approaches that will be used for the review are described below. … Assessments of individual study eligibility based upon sample size will be conducted and fully described … this standardized quality assessment tool, we will apply quality criteria specific to ‘harms’ as described … the retrieval of a manageable set of citations with clearly defined study populations and uniformly described

290. Ch 1-User-Guide-To-Ocer 130129 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/ch_1-user-guide-to-ocer_130129.pdf
     August 13, 2012 - questions and study objectives for conducting observational comparative effectiveness research (CER) are described … frame for regulatory, ethical, or other reasons, this interval should be expressed to researchers and described … These assumptions should be described in the study protocol and in reporting final study results. … For studies that are described in the protocol as preliminary, this may also help readers understand … The principles described in this chapter are intended to strengthen the writing of research protocols

291. MEDICAL MANAGEMENT OF CONGESTIVE HEART FAILURE AND THE EFFECTIVENESS OF ISOSORBIDE DINITRATE AND HYDRALAZINE (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/congestive-heart-failure-medicines_research.pdf
     March 01, 2010 - patients (62% of the total) and took a random sample of 20% of Whites (excluding 25% of the total) as described … Comorbidities were identified in the year prior to HF diagnosis according to groups of ICD-9 codes described … exposure variable treated as a time-dependent covariate.15-17 Comorbidities and other risk variables described … dependent variable any use of H-ISDN within six months of HF diagnosis and all the independent variables described

292. Gout-managment-protocol-141103 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/gout_research-protocol.pdf
     November 03, 2014 - Exclusion of Studies in the Review - Included studies will be limited to those that fit the PICOTs described … Data Abstraction and Data Management – Data abstraction will follow the procedures described above. … are of similar sample size, we will explore using the Hartung, Knapp, Sidik and Jonkman method, as described … For studies not included in pooled analyses, outcomes will be described narratively, stratified by comparisons

293. Obesity Prevention and Control (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/obesity-research-methods_research-protocol.pdf
     February 08, 2017 - Analytic Framework The following figure depicts the key questions within the context of the PICOTS described … Studies measuring a specific macronutrient not described above (e.g., protein intake) or specific vitamin … Studies assessing other dietary or physical activity behaviors not described above (e.g. … selected through independent screening by two screeners based on the inclusion and exclusion criteria described … how the data systems have been linked together using information obtained from the article, and as described

294. Evidence Report on the (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/atypical-antipsychotics-off-label-update_research-protocol.pdf
     May 19, 2010 - Online: May 19, 2010 Population: Demographic, clinical, and severity subsets of the populations described … of this Comparative Effectiveness Review, with the five key questions depicted within the context described … Exclusion of Studies in the Review The included populations, interventions, comparators, and outcomes are described

295. Technical Brief Disposition of Comments Report for Gene Expression Profiling for Predicting Outcomes in Stage II Colon Cancer (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/colon-cancer-gene-profiling_disposition-comments.pdf
     December 14, 2012 - The limitations of the existing studies were very well described. … The GEPs analyze/measure RNA and this is done using the various techniques described; and use of DNA … The other tests described in your review have been based on studies in convenience samples, and have … scientific developments (response to request in Draft Brief for additional detail) The pooled analyses described

296. Research White Paper: Outcome Measure Harmonization and Data Infrastructure for Patient-Centered Outcomes Research in Depression (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/white-paper-outcome-measure-harmonization-depression.pdf
     November 01, 2020 - These steps are described further below. … These steps are described further below. … Because APA and ABFM work with the same registry technical vendor, the process is similar to the steps described … Potential challenges related to the availability of PHQ-9, adverse event, suicide, and mortality data are described

297. Integrating Stakeholder Preferences in Comparative Effectiveness Research: Potential Uses of Multi-Criteria Decision Analysis (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/mcda_mohr.pdf
     August 27, 2012 - Integrating Stakeholder Preferences in Comparative Effectiveness Research: Potential Uses of Multi-Criteria Decision Analysis Slide 1 Integrating Stakeholder Preferences in Comparative Effectiveness Research: Potential Uses of Multi-Criteria Decision Analysis Techniques August 27, 2012 Effective Health Care …

298. Registry of Patient Registries (RoPR): Project Overview (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/registry-of-patient-registries_research-2012-3_0.pdf
     January 01, 2012 - Research Report Number 40 4 Architectural Design In consideration of the goals and constraints described … Effective Health Care Program Research Report Number 40 6 Summary The hybrid design model described

299. Engaging Stakeholders to Identify and Prioritize Topics for Future Research: Recommended activities and reporting practices (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/stakeholders-engagement-others_research-2011.pdf
     January 01, 2011 - Engaging Stakeholders to Identify and Prioritize Topics for Future Research: Recommended activities and reporting practices 1 Engaging Stakeholders to Identify and Prioritize Topics for Future Research: Recommended activities and reporting practices This table presents a series of recommended activities for resea…

300. genetic-testing-developmental-disabilities-protocol-140930 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/genetic-testing-developmental-disabilities_research-protocol.pdf
     September 30, 2014 - Clinical validity is usually described in terms of clinical sensitivity, clinical specificity, positive … Scope of Work The scope of work for this Technical Brief is described below by the population, … Table 5 is an evidence map previously described.